Deccan Health Care Fair Value
Deccan Health Care (DECCAN) average fair value is ₹29.37 across 5 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, vs a current market price of ₹12.78 (+129.84%), fair value range ₹11.26–₹46.09. Examine DECCAN Q4 results for recent quarterly revenue, profit and EPS trends.
Fair Value Analysis Export
DECCAN Fair Value vs Current Price — Valuation Summary
DECCAN average fair value, fair value range, price gap and valuation status across 5 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number. For live price and a broader fundamental view, visit Deccan Health Care share price screener.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
DECCAN Fair Value Analysis — Data Sources & Coverage
Deccan Health Care financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. See DECCAN book value comparison to compare market price against book value per share.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
DECCAN vs Healthcare Services Sector Peers — P/E, P/B & Market Cap
Deccan Health Care P/E ratio, P/B ratio and market capitalisation vs Healthcare Services sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| One Global Service Provi… | ONEGLOBAL | 14.84 | 9.12 | ₹920 |
| Suraksha Diagnostic | SURAKSHA | 40.64 | 5.71 | ₹1,356 |
| Gujarat Kidney and Super… | GKSL | 83.28 | 3.9 | ₹1,117 |
| Invicta Diagnostic | INVICTA | 17.24 | 1.68 | ₹80 |
| Jupiter Life Line Hospit… | JLHL | 44.49 | 5.79 | ₹8,320 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.